GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the “Units”). Each warrant (a “Warrant”) entitles the holder to purchase one-half of a share of Common Stock at price of $115 per share.
Latest posts by GlobeNewswire (see all)
- Keiretsu Forum Mid-Atlantic, South-East, Texas’ Investor Capital Expo Honors Top Startups with the Stephen M. Goodman Most Valued Company Award - November 6, 2024
- CORRECTION: Cellebrite Announces Third-Quarter 2024 Results - November 6, 2024
- University of Kansas Medical Center Enhances Robotic Heart Care Program with Genesis Robotic Technology - November 6, 2024